← Product Code [GEX](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX) · K130681 # ENDOVASCULAR LASER VENOUS SYSTEM KIT WITH 2 RING RADIAL EMITTING FIBER (K130681) _Biolitec Sia · GEX · Jan 8, 2014 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K130681 ## Device Facts - **Applicant:** Biolitec Sia - **Product Code:** [GEX](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX.md) - **Decision Date:** Jan 8, 2014 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 878.4810 - **Device Class:** Class 2 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic ## Intended Use The device is intended for endovascular coagulation of blood vessels. The device is indicated for the endovascular coagulation of the Greater Saphenous Vein of the thigh in patients with superficial vein reflux. ## Device Story Endovascular Laser Venous System (ELVeS) kit utilizes 2-ring radial fiber to perform endovascular laser ablation (EVLA) of veins. Kit includes 2-ring radial fiber, access needle, introducer sheath/dilator, and guidewire. Device operates by delivering laser energy to induce circumferential coagulation of vein walls. Used by physicians in clinical settings to treat superficial vein reflux, including large diameter (>8mm and >12mm) Greater Saphenous Veins (GSV) and Small Saphenous Veins (SSV). 2-ring radial design provides two adjacent points of radial emission, enabling homogenous radiation, reduced energy requirements, and lower recanalization rates compared to single-ring fibers. Clinical benefits include high occlusion rates, reduced adverse events (bruising, pain, induration, numbness), and improved venous clinical severity scores. Procedure is minimally invasive, resulting in high patient satisfaction. ## Clinical Evidence Clinical effectiveness supported by multiple studies. One study showed 2-ring radial fiber reduced recanalization rates, energy (Watt/LEED) requirements, and adverse events (pain, bruising, numbness) compared to standard EVLA. Another study on large GSV (>8mm) showed effective treatment with optimal homogenous radiation and high patient satisfaction. A comparative study against radio frequency (RF) energy in very large GSV (>12mm) showed no statistically significant difference in VCSS improvement or patient satisfaction, confirming safety and efficacy. Bench testing confirmed compliance with electrical safety (IEC 601-2-22, ANSI/AAMI ES1) and biocompatibility (ISO 10993-7) standards. ## Technological Characteristics Kit includes 2-ring radial fiber, access needle, introducer sheath/dilator, and guidewire. Features 2 adjacent points of radial emission. Complies with 21 CFR 1040.10/1040.11, ANSI/AAMI ES1, IEC 601-2-22, EN 60825-1, and ANSI/AAMI/ISO 10993-7. Sterilized via validated cycles. Standalone surgical accessory used with compatible laser systems. ## Regulatory Identification (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon. ## Predicate Devices - ELVeS Kit with Radial Fiber - Evolve HPD 980-1470nm Multiwavelength ([K101712](/device/K101712.md)) - Ceralas 1470, 980 and 810nm ELVeS kits ([K112299](/device/K112299.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K130681 Page 1 of 2 JAN - 8 2014 # K130681 - 510(k) Summ Endovascular Laser Venous System Kit with 2 Ring Radial En # Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared Biolitec SIA Kaniera iela 10a, Riga, LV-1063 Latvia * (413) 525-0600 or 413-250-0779 Phone: Facsimile: * (413) 525-0611 Contact Person: *Harry Hayes, Ph.D. – Regulatory Consultant Date prepared: March 4, 2013 # Name of Device and Name/Address of Sponsor Endovascular Laser Venous System Kit (ELVeS®) with 2 Ring Radial K Biolitec SIA Kaniera iela 10a, Riga, LV-1063 Latvia Classification Name Surgical laser accessories ## Predicate Devices ELVeS Kit with Radial Fiber ## Intended Use/Indication for Use The device is intended for endovascular coagulation of blood vessels. Th indicated for the endovascular coagulation of the Greater Saphenous Vein of the thigh in patients with superficial vein reflux. # Technological Characteristics The ELVeS kit with 2 Ring Radial Fibers contain the following components: (1) 2 ring radial fiber; (2) access needle; (3) introducer sheath/ dilator; and (4) a guidewire and is identical to that cleared under K101712 and K112299 except for the 2 ring radial tip design. The design provides 2 adjacent points of radial emission. {1}------------------------------------------------ ### Performance Data The device complies with the following voluntary consensus standards: 21 C.F.R. & 1040.10 & 1040.11; ANSI/AAMI ES1; IEC 601-2-22; EN 60825-1. and ANSI/AAMI/ISO 10993-7. The clinical effectiveness is equivalent to its predicate devices, as evidence by several clinical evaluations. In one study, the circumferential ablation of the vein with introduction of the 2 ring radial fiber provided a better outcome following EVLA: 1) reduction in recanalization rates 2) reduction in applied Watt/LEED. & 3) reduction in adverse events; including bruising, pain, induration & numbness. The study supported the conclusion concluded that EVLA with 2 ring radial fiber for GSV and SSV is an effective and safe procedure, giving the advantage of decreasing delivered energy during the procedure and also providing very good occlusion rates with lowered rates of side/adverse effects. Another study demonstrated an effective method to treat large insufficient GSV (diameter above 8 mm) by using the 2 ring radial-fiber. The procedure needed less energy and resulted in an optimal homogenous radiation. The patient satisfaction rate was high and the clinical evaluators could demonstrate that modified CEAP severity was much better after 1&2 days. No significant difference was observed in the occlusion-rate between subgroups of >8mm dia. and <8mm dia. A further study compared the efficacy, adverse events, occlusion rates, patient satisfaction and changes in venous clinical severity scores in the treatment of very large diameter (>12 mm) greater saphenous veins (GSV) with the 2 ring radial fiber compared to radio frequency (RF) energy. VCSS scores were improved after the procedures and there was no statistically significant difference between groups. There was also no statistically significant difference in patient satisfaction between groups. Both treatment modalities were safe and effective in the treatment of very large diameter GSVs. The 2-ring radial fiber also resulted in almost no pain. Sterilization cycle parameters and the validation reports showed an acceptable sterility was achieved with the device. #### Substantial Equivalence The ELVeS with 2 Ring Radial Fiber is substantially identical to that cleared under K101712 and K112299 and has the same intended use and indications for use as the cleared Evolve HPD 980-1470nm Multiwavelength and Ceralas 1470, 980 and 810nm ELVeS kits. Thus, the ELVeS with 2 Ring Radial Fiber is substantially equivalent to its predicate devices. {2}------------------------------------------------ #### DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 Biolitec SIA Dr. Harry Hayes Regulatory Consultant Kaniera iela 10a Riga, LV-1063 Latvia January 8, 2014 Re: K130681 Trade/Device Name: Endo Laser Vein System Kit with 2 Ring Radial Fiber Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: GEX Dated: November 22, 2013 Received: December 11, 2013 Dear Dr. Hayes: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act {3}------------------------------------------------ Page 2 - Dr. Harry Hayes or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542.of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CER Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, # Joshua G. Nipper -S Binita S. Ashar, M.D., M.B.A., F.A.C.S. Acting Director For Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ Indications for Use Statement 510(k) Number (if known): _K130681_ Device Name: Endo Laser Vein System Kit with 2 Ring Radial Fiber Endovascular Coagulation of the Greater Saphenous Vein of the thigh in patients with superficial vein reflux. (PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use _ OR Over The Counter Use (Per 21 C.F.R. 801.109) (Optional Format 1-2-96) Image /page/4/Picture/7 description: The image contains a combination of text and symbols. The text includes "Neil R" and "2014.01". There is also a symbol that appears to be a stylized logo or emblem, possibly related to an organization or company. The image also contains the characters "-05'00'". (Division Sign-Off) for BSA Division of Surgical Devices 510(k) Number _K130681 --- **Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K130681](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K130681) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com